柳叶刀 | 早期临床试验显示，Amycretin有望成为新型减重疗法

Declaration of interests

The phase 1 trial was funded by Novo Nordisk A/S.

AG, AH, SG, JBH, KK, TK, SBP, ST, and AV are employees of and shareholders in Novo Nordisk A/S. CK is an employee of ICON (contract research organisation). ICON received funding from Novo Nordisk A/S for conducting the clinical study described in this manuscript, for which CK was the principal investigator.

The 1b/2a trail was funded by Novo Nordisk.

KD, ST, SD, RDdV, AF, AG, AH, SBP, AV, and KA are employees of and shareholders in Novo Nordisk. CK is an employee of ICON, which received funding from Novo Nordisk for conducting the clinical study described in this manuscript, for which CK was the principal investigator. AMJ reports conduct of multicentre trials with Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Rhythm Pharmaceuticals; serving on scientific advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Eli Lilly, Intellihealth, Metsera, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Roche, Scholar Rock, State 4 Therapeutics, Structure Therapeutics, Syntis Bio, Terns Pharmaceuticals, WeightWatchers, and Zealand Pharmaceuticals; institutional grant funding from the US National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases); travel support from Amgen, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, and WeightWatchers; participation on a data safety monitoring board for the University of Minnesota (two studies); serving on the governance board for The Obesity Society, the Obesity Algorithm Task Force of the American Association of Clinical Endocrinologists; being an Associate Editor for the American Diabetes Association and Diabetes Care; holding stock or stock options with Intellihealth, State 4 Therapeutics, and Syntis Bio; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Novo Nordisk.